BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Harvard Global Health Institute - ECPv6.5.1.4//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Harvard Global Health Institute
X-ORIGINAL-URL:https://globalhealth.harvard.edu
X-WR-CALDESC:Events for Harvard Global Health Institute
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Halifax
BEGIN:DAYLIGHT
TZOFFSETFROM:-0400
TZOFFSETTO:-0300
TZNAME:ADT
DTSTART:20240310T060000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0300
TZOFFSETTO:-0400
TZNAME:AST
DTSTART:20241103T050000
END:STANDARD
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Halifax:20241112T120000
DTEND;TZID=America/Halifax:20241112T124500
DTSTAMP:20260823T085936
CREATED:20241008T144127Z
LAST-MODIFIED:20241121T220229Z
UID:10000830-1731412800-1731415500@globalhealth.harvard.edu
SUMMARY:Advancing Global Adolescent Health and Nutrition: Insights from the ARISE Network
DESCRIPTION:  \nAdequate nutrition during adolescence can profoundly impact health and well-being in the present\, continuing into adulthood\, and extending to future generations. Evidence from our recent observational and intervention studies demonstrates the effectiveness of integrated approaches in mitigating malnutrition. Dr. Fawzi’s will discuss his research which focuses on addressing pressing health challenges in countries such as Tanzania\, Uganda\, Sudan\, and India. His primary interests include the design and implementation of randomized controlled trials and observational studies targeting maternal\, neonatal\, and child health\, as well as infectious diseases\, with a special emphasis on the role of nutrition. Dr. Louise Ivers will moderate the session. \nThe event is free and open to the public. \nAbout the Speakers\n\nWafaie Fawzi\, MBBS\, MPH\, MS\, DrPH\, Professor of Nutrition\, Epidemiology\, and Global Health at Harvard T.H. Chan School of Public Health \nWafaie Fawzi\, MBBS\, MPH\, MS\, DrPH is a physician and epidemiologist focused on advancing global health research\, education\, and practice. He is Professor of Nutrition\, Epidemiology\, and Global Health at Harvard T.H. Chan School of Public Health. He established and continues to lead the Nutrition and Global Health Program\, an interdepartmental initiative at Harvard where over the past 25 years he sought to strengthen the evidence base for advancing human health and development. He is an elected member of the National Academy of Medicine. \n  \n  \n \nLouise C. Ivers\, MD\, MPH\, DTM&H\, Faculty Director\, Harvard Global Health Institute \nDr. Louise C. Ivers\, MD\, MPH\, DTM&H is the Faculty Director of the Harvard Global Health Institute and the Executive Director of the Massachusetts General Hospital (MGH) Center for Global Health. Dr. Ivers is also the David Bangsberg Endowed Chair in Global Health Equity at MGH and a Professor of Medicine and Professor of Global Health and Social Medicine at Harvard Medical School. Dr. Ivers has spent her career providing care to the rural and urban poor and engaging in patient-oriented investigation that offer solutions to barriers to healthcare. She works on the design\, implementation\, and evaluation of large-scale public health programs in resource-limited settings with the goal of achieving health equity. She has worked on healthcare delivery in India\, Southeast Asia\, and Africa. From 2003-2017\, Dr. Ivers served in various leadership roles for Partners in Health\, including Clinical Director\, Chief of mission\, and Director of strategic implementation. In addition to expanding access to healthcare for the poor\, Dr. Ivers has contributed to published research articles on HIV/AIDS\, food insecurity\, and cholera treatment and prevention and is involved in global policy and advocacy.
URL:https://globalhealth.harvard.edu/event/advancing-global-adolescent-health-and-nutrition/
LOCATION:Virtual
CATEGORIES:Virtual
ATTACH;FMTTYPE=image/png:https://globalhealth.harvard.edu/wp-content/uploads/2024/10/Dr.-Fawzi-RI-Speaker-Series-Promo-Image-900-x-600px.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Halifax:20241008T120000
DTEND;TZID=America/Halifax:20241008T124500
DTSTAMP:20260823T085936
CREATED:20240910T153534Z
LAST-MODIFIED:20241112T211448Z
UID:10000819-1728388800-1728391500@globalhealth.harvard.edu
SUMMARY:Hunger\, Food Security\, and the Race to Produce New Seeds for a Climate-Changed World
DESCRIPTION:Many of the world’s most productive agricultural regions are increasingly vulnerable to extreme droughts\, floods\, and unpredictable weather patterns. As climate change forces farmers to migrate and adapt\, the ripple effects on global food systems and public health will be felt for decades. In response\, crop research centers are racing to develop new seed varieties that can withstand these harsh conditions. Drawing on lessons from the mid-twentieth century efforts to rapidly increase food production\, this session explores the urgent need for innovation in food production\, highlighting the long-term impacts on the environment\, health\, and food security. Dr. Gabriela Soto Laveaga will discuss how this race for resilience will shape the future of global health and well-being. Dr. Megan Murray will moderate the conversation. \nThe event is free and open to the public. \nAbout the Speakers\n \nGabriela Soto Laveaga\, PhD\, MA\, Professor of the History of Science and Antonio Madero Professor for the Study of Mexico at Harvard University \nGabriela Soto Laveaga is Professor of the History of Science and Antonio Madero Professor for the Study of Mexico at Harvard University. Her award-winning first book Jungle Laboratories: Mexican Peasants\, National Projects and the Making of the Pill narrated the impact of the search for medicinal plants at the local\, national\, and global level. Her award-wining articles have ranged from examining the role of indigenous midwives in the Mexican healthcare system\, the use of soap operas to deliver public health messaging\, Latin American innovation in science and medicine\, and how we narrate histories of science outside of so-called centers of innovation. She is completing two book manuscripts: one on doctors as agents of social unrest and her third book which examines agricultural science exchange between India and Mexico. She has been a fellow at the Institute of Advanced Study at Princeton\, held the Dibner Distinguished fellowship in History of Science and Technology at the Huntington Library\, among other awards. Most recently she was elected to the Academia Mexicana de la Historia\, one of the highest honors for a historian of Mexico\, especially one outside of the country. She is also a past recipient of the Everett Mendelsohn Excellence in Graduate Mentoring Award. \n  \n \nMegan Murray\, ScD\, MD\, Ronda Stryker and William Johnston Professor of Global Health\, Harvard Medical School; Director of Research\, Global Health & Social Medicine\, Harvard Medical School \nMegan Murray is an epidemiologist and an infectious disease physician\, with over 25 years of experience studying tuberculosis and other infectious diseases. She received her MD from Harvard Medical School in 1990 and completed her residency in internal medicine and a fellowship in Infectious Disease at Massachusetts General Hospital. She received her ScD in Epidemiology from the Harvard School of Public Health in 2000. She currently serves as the Ronda Stryker and William Johnston Professor of Global Health and Social Medicine at Harvard Medical School and as a Professor of Epidemiology at the Harvard Chan School of Public Health. \nDr. Murray’s research focuses on social\, host and pathogen specific determinants of TB infection\, disease and treatment outcomes. She studies nutritional risk factors for TB infection and disease\, including macronutrients status and the role of Vitamins A\, E and D. She uses bacterial and human genetic and genomic tools to identify variants of interest and their role in TB. \n  \nAbout the Global Research and Innovation Speaker Series\nThe Harvard Global Health Institute’s Global Health Research and Innovation Speaker Series showcases the latest scholarly and scientific advancements in global health across Harvard and beyond\, to make cutting-edge research accessible to a diverse global audience\, and to spark innovative solutions in the pursuit of health equity and improved health outcomes worldwide. The public series takes place virtually on the second Tuesday of each month from 12:00 to 12:45 pm ET. Each session will include a presentation by a featured speaker showcasing their innovative research in global health\, followed by a moderated Q&A. \nSpeakers will share their own perspectives; they do not speak for Harvard.
URL:https://globalhealth.harvard.edu/event/hunger-food-security-and-the-race-to-produce-new-seeds/
LOCATION:Virtual
CATEGORIES:Virtual
ATTACH;FMTTYPE=image/png:https://globalhealth.harvard.edu/wp-content/uploads/2024/09/Soto-RI-Speaker-Series-Mailchimp-Image-Template-900-x-600px.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Halifax:20240910T120000
DTEND;TZID=America/Halifax:20240910T124500
DTSTAMP:20260823T085936
CREATED:20240827T142350Z
LAST-MODIFIED:20240828T150140Z
UID:10000249-1725969600-1725972300@globalhealth.harvard.edu
SUMMARY:Impact of Arbovirus Infection on Pregnancy
DESCRIPTION:  \n \nThe adverse impact of Zika (ZIKV)\, dengue (DENV)\, and chikungunya (CHIKV) virus infection in pregnancy has been recognized in Latin America and Asia but is not well studied in Africa. Although originally discovered in sub-Saharan Africa\, the non-specific clinical presentation of arbovirus infection may have hampered our detection of adverse clinical outcomes and outbreaks. This prospective study of arbovirus infection in pregnant women in north-central Nigeria sought to characterize the prevalence of acute arbovirus infection and determine the impact on pregnancy and infant outcomes. \nDr. Phyllis Kanki will talk about her research on this important topic and attendees are encouraged to join the discussion by sending us their questions. Dr. Louise Ivers will moderate the conversation. \nThe event is free and open to the public. \nAbout the Speakers\n\nPhyllis Kanki\, DVM\, DSc\, Mary Woodard Lasker Professor of Health Sciences \nPhyllis Kanki is the Mary Woodard Lasker Professor of Health Sciences at the Harvard T. H. Chan School of Public Health. She has worked in West Africa since 1984\, where her research in Senegal provided the initial characterization of HIV-2\, demonstrated reduced virulence\, transmission and progression to disease and interactions with HIV-1 subtypes. In 2000\, she founded the AIDS Prevention Initiative in Nigeria (APIN)\, supported by the Bill & Melinda Gates Foundation modeled after the Senegal research collaboration. She led Harvard’s President’s Emergency Plan for AIDS Relief (PEPFAR) program supporting prevention\, care and HIV antiretroviral therapy for over 200\,000 patients in Nigeria\, Botswana\, and Tanzania (2005-2013). In West Africa\, following epidemics of Ebola (EBOV) and Zika virus (ZIKV)\, she documented the multi-decade presence of ZIKV\, demonstrating the endemicity of this unique arbovirus in the region. She described the longevity\, specificity and cross reactivity of T cell responses to ZIKV and DENV and characterized the T cell responses in survivors and exposed health care workers from the 2015 Nigeria EBOV outbreak. She has just completed a 3 year study of ZIKV\, dengue and Chikungunya virus infection in pregnant women and documenting associated microcephaly and other birth abnormalities. \n  \n \nLouise C. Ivers\, MD\, MPH\, DTM&H\, Faculty Director\, Harvard Global Health Institute \nDr. Louise C. Ivers\, MD\, MPH\, DTM&H is the Faculty Director of the Harvard Global Health Institute and the Executive Director of the Massachusetts General Hospital (MGH) Center for Global Health. Dr. Ivers is also the David Bangsberg Endowed Chair in Global Health Equity at MGH and a Professor of Medicine and Professor of Global Health and Social Medicine at Harvard Medical School. Dr. Ivers has spent her career providing care to the rural and urban poor and engaging in patient-oriented investigation that offer solutions to barriers to healthcare. She works on the design\, implementation\, and evaluation of large-scale public health programs in resource-limited settings with the goal of achieving health equity. She has worked on healthcare delivery in India\, Southeast Asia\, and Africa. From 2003-2017\, Dr. Ivers served in various leadership roles for Partners in Health\, including Clinical Director\, Chief of mission\, and Director of strategic implementation. In addition to expanding access to healthcare for the poor\, Dr. Ivers has contributed to published research articles on HIV/AIDS\, food insecurity\, and cholera treatment and prevention and is involved in global policy and advocacy.
URL:https://globalhealth.harvard.edu/event/research-and-innovation-speaker-series-2024-09-10/
LOCATION:Virtual
CATEGORIES:Virtual
ATTACH;FMTTYPE=image/png:https://globalhealth.harvard.edu/wp-content/uploads/2024/08/Phyllis-Kanki-RI-Speaker-Series-Promo-Image-900-x-600-px.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Halifax:20240618T120000
DTEND;TZID=America/Halifax:20240618T124500
DTSTAMP:20260823T085936
CREATED:20240605T145532Z
LAST-MODIFIED:20240617T204743Z
UID:10000233-1718712000-1718714700@globalhealth.harvard.edu
SUMMARY:Climate Change and Respiratory Health: From Epidemiology to Intervention
DESCRIPTION:  \n \nDr. Mary B. Rice will discuss research on the respiratory health effects of climate change and opportunities for physicians and scientists to intervene at the clinical and policy level. \nDr. Satchit Balsari will moderate the session\, with an introduction by Dr. Louise C. Ivers. \nThis event is free and open to the public. \nAbout the Speakers\n \nMary B. Rice\, MD\, MPH\, Director of the BIDMC Institute for Lung Health\, Associate Professor of Medicine at Harvard Medical School \nDr. Rice’s research focuses on preventable causes of chronic lung disease in children and adults\, including environmental exposures such as air pollution\, climate\, aeroallergens and microbes. Dr. Rice is the Director of the BIDMC Institute for Lung Health\, a multi-disciplinary respiratory research program that applies advanced statistical and sampling methodologies in clinical populations with chronic lung disease and multiple U.S.-based prospective cohort studies of children and adults. A core mission is to identify preventable causes of chronic lung disease\, and to translate research findings into patient care and health policies that improve lung health. Dr. Rice’s research is funded by the National Institutes of Health. \n  \n  \n \nSatchit Balsari\, MD\, MPH\, Associate Professor\, Emergency Medicine\, Harvard Medical School and Beth Israel Deaconess Medical Center; Department of Global Health and Population\, Harvard T.H. Chan School of Public Health \nDr. Satchit Balsari is Associate Professor in Emergency Medicine at Harvard Medical School and Beth Israel Deaconess Medical Center; and in the Department of Global Health and Population at the Harvard T.H. Chan School of Public Health. Dr. Balsari’s research and teaching are focused on complex humanitarian emergencies and digital health implementation science in resource-poor settings. He has worked with populations affected by disaster\, war and the COVID-19 pandemic in Iraq\, South Sudan\, Jordan\, Haiti\, Puerto Rico and across South Asia. In the most vulnerable communities in the world\, his team has leveraged cutting-edge digital tools and citizen science to advance public health planning\, advocacy\, and response. \nThe Balsari Lab collaborates directly with populations in distress\, humanitarian response agencies\, civil society organizations\, governments\, and international agencies\, to reduce the information asymmetry that threatens to exclude the poor and disadvantaged from decisions that will impact their lives. Dr. Balsari co-directs CrisisReady.io\, a research-response platform that builds data-driven decision tools for local communities and response agencies affected by disasters globally. Dr. Balsari is founding director of the tri-institute Climate and Human Health fellowship at Harvard\, leads the climate platform at the Lakshmi Mittal and Family South Asia Institute\, and is co-investigator on the Salata Institute’s inaugural interfaculty cluster grant on Climate Change Adaptation in South Asia. He recently has curated an exhibition\, Hum Sab Ek\, which is based on his research on the impact of the COVID-19 pandemic on the 2.9 million-strong Self Employed Women’s Association (SEWA)\, and its members’ response to it. \nPrior signature initiatives include EMcounter (a customizable\, portable digital surveillance tool\, the latest iteration of which was used at the world’s largest mass gathering\, the Kumbh Mela in India) and Voices\, a crowd-sourced\, online disaster response analysis tool. In 2018\, in collaboration with Professor Caroline Buckee (Epidemiology)\, he co-led the Hurricane Maria Mortality Study. \n  \n \nLouise C. Ivers\, MD\, MPH\, DTM&H\, Faculty Director\, Harvard Global Health Institute \nDr. Louise C. Ivers\, MD\, MPH\, DTM&H is the Faculty Director of the Harvard Global Health Institute and the Executive Director of the Massachusetts General Hospital (MGH) Center for Global Health. Dr. Ivers is also the David Bangsberg Endowed Chair in Global Health Equity at MGH and a Professor of Medicine and Professor of Global Health and Social Medicine at Harvard Medical School. Dr. Ivers has spent her career providing care to the rural and urban poor and engaging in patient-oriented investigation that offer solutions to barriers to healthcare. She works on the design\, implementation\, and evaluation of large-scale public health programs in resource-limited settings with the goal of achieving health equity. She has worked on healthcare delivery in India\, Southeast Asia\, and Africa. From 2003-2017\, Dr. Ivers served in various leadership roles for Partners in Health\, including Clinical Director\, Chief of mission\, and Director of strategic implementation. In addition to expanding access to healthcare for the poor\, Dr. Ivers has contributed to published research articles on HIV/AIDS\, food insecurity\, and cholera treatment and prevention and is involved in global policy and advocacy.
URL:https://globalhealth.harvard.edu/event/research-and-innovation-speaker-series-3-2/
LOCATION:Virtual
ATTACH;FMTTYPE=image/png:https://globalhealth.harvard.edu/wp-content/uploads/2024/06/Mary-Rice-6-18-2024-900-x-600px-no-QR-code.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20240514T120000
DTEND;TZID=UTC:20240514T124500
DTSTAMP:20260823T085936
CREATED:20240506T132924Z
LAST-MODIFIED:20240506T152429Z
UID:10000227-1715688000-1715690700@globalhealth.harvard.edu
SUMMARY:Innovation in the Treatment of Drug-resistant Tuberculosis: The endTB Clinical Trial
DESCRIPTION:LEARN MORE/REGISTER \nIn this Global Health Research and Innovations Speaker Series event\, Dr. Carole Diane Mitnick\, ScD\, Professor of Global Health and Social Medicine at Harvard Medical School will share her work on the endTB clinical trial. Dr. Louise C. Ivers\, MD\, MPH\, DTM&H\, Faculty Director at the Harvard Global Health Institute\, will moderate the conversation. \nPLEASE CLICK HERE TO REGISTER \nEvent Description\nFor decades\, poor treatment options and low-quality evidence plagued care for rifampin-resistant tuberculosis (RR-TB). The advent of new anti-TB drugs and enhanced funding now permit randomized controlled trials of shortened\, all-oral treatment for resistant TB. \nMethods \nendTB is an international\, open-label\, Phase 3 non-inferiority\, randomized\, controlled clinical trial to compare five 9-month all-oral regimens including bedaquiline (B)\, delamanid (D)\, linezolid (L)\, levofloxacin (Lfx) or moxifloxacin (M)\, clofazimine (C) and pyrazinamide (Z)\, to the standard (control) for treatment of fluoroquinolone-susceptible RR-TB. Participants were randomized to 9BLMZ\, 9BCLLfxZ\, 9BDLLfxZ\, 9DCLLfxZ\, 9DCMZ and control using Bayesian response-adaptive randomization. The primary outcome was favorable outcome at week 73 defined by two negative sputum culture results or by favorable bacteriologic\, clinical\, and radiologic evolution. The non-inferiority margin was 12 percentage points. \nResults \nOf 754 randomized patients\, 696 and 559 were included in the modified intention to treat (mITT) and per-protocol (PP) analyses\, respectively. In mITT\, the control had 80.7% favorable outcomes. Regimens 9BCLLfxZ [adjusted risk difference (aRD): 9.5% (95% confidence interval (CI)\, 0.4 to 18.6)]\, 9BLMZ [aRD: 8.8% (95%CI\, -0.6 to 18.2)]\, and 9BDLLfxZ [3.9% (95%CI\, -5.8 to 13.6)] were non-inferior in mITT and in PP. The proportion of participants experiencing grade 3 or higher adverse events was similar across the regimens. Grade 3 or higher hepatotoxicity occurred in 11.7% of the experimental regimens overall and in 7.1% of the control. \nConclusions \nThe endTB trial increases treatment options for RR-TB with three shortened\, all-oral regimens that were non-inferior to a current well-performing standard of care. \nPLEASE CLICK HERE TO REGISTER \nAbout the Speakers\nCarole Diane Mitnick\, ScD\, Professor of Global Health and Social Medicine\, Harvard Medical School \nDr. Mitnick is Professor of Global Health & Social Medicine at Harvard Medical School (HMS) and Associate Epidemiologist in the Division of Global Health Equity at Brigham & Women’s Hospital. She has 25 years of experience in programmatic support\, research (observational and experimental)\, policy\, and advocacy related to increased access to high-quality\, appropriate treatment for TB\, especially for drug-resistant TB. Dr. Mitnick works in close collaboration with Partners In Health\, specifically in Peru\, Haiti\, Kazakhstan\, and Lesotho. In addition to teaching at HMS and giving lectures at other institutions\, Dr. Mitnick mentors trainees in the HMS Master of Medical Science in Global Health Delivery Program. She is the co-PI of the endTB and endTB-Q trials\, two multi-country\, Phase III\, randomized\, controlled\, clinical trials of all-oral\, shortened\, novel regimens for rifampin-resistant TB. She has also recently begun conducting research on post-TB lung disease. \nLouise C. Ivers\, MD\, MPH\, DTM&H\, Faculty Director\, Harvard Global Health Institute; Executive Director\, Massachusetts General Hospital Center for Global Health \nDr. Louise C. Ivers\, MD\, MPH\, DTM&H is the Faculty Director of the Harvard Global Health Institute and the Executive Director of the Massachusetts General Hospital (MGH) Center for Global Health. Dr. Ivers is also the David Bangsberg Endowed Chair in Global Health Equity at MGH and a Professor of Medicine and Professor of Global Health and Social Medicine at Harvard Medical School. Dr. Ivers has spent her career providing care to the rural and urban poor and engaging in patient-oriented investigation that offer solutions to barriers to healthcare. She works on the design\, implementation\, and evaluation of large-scale public health programs in resource-limited settings with the goal of achieving health equity. She has worked on healthcare delivery in India\, Southeast Asia\, and Africa. From 2003-2017\, Dr. Ivers served in various leadership roles for Partners in Health\, including Clinical Director\, Chief of mission\, and Director of strategic implementation. In addition to expanding access to healthcare for the poor\, Dr. Ivers has contributed to published research articles on HIV/AIDS\, food insecurity\, and cholera treatment and prevention and is involved in global policy and advocacy. \nAbout the Global Health Research and Innovation Speaker Series\nThe Harvard Global Health Institute’s Global Health Research and Innovation Speaker Series showcases the latest scholarly and scientific advancements in global health across Harvard and beyond\, to make cutting-edge research accessible to a diverse global audience\, and to spark innovative solutions in the pursuit of health equity and improved health outcomes worldwide. The public series takes place virtually on the second Tuesday of each month from 12:00 to 12:45 pm ET. Each session will include a presentation by a featured speaker showcasing their innovative research in global health\, followed by a moderated Q&A. \nSpeakers will share their own perspectives; they do not speak for the university.
URL:https://globalhealth.harvard.edu/event/innovation-in-the-treatment-of-drug-resistant-tuberculosis-the-endtb-clinical-trial/
LOCATION:Virtual
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Halifax:20240409T120000
DTEND;TZID=America/Halifax:20240409T124500
DTSTAMP:20260823T085936
CREATED:20240312T124949Z
LAST-MODIFIED:20240517T195704Z
UID:10000219-1712664000-1712666700@globalhealth.harvard.edu
SUMMARY:Global Health Research and Innovation Speaker Series with Milind Tambe
DESCRIPTION:For over 15 years\, Dr. Tambe and his team have been focused on AI for social impact\, deploying end-to-end systems in areas of public health\, conservation\, and public safety. In this talk\, he will highlight the results from their deployments for social impact in public health\, as well as required innovations in integrating machine learning and optimization. Dr. Tambe will present recent results from their work in India with the world’s two largest mobile health programs for maternal and childcare that have served millions of beneficiaries\, and on-going projects focused on other mobile health programs. Additionally\, he will highlight results from an earlier project on HIV prevention among youth experiencing homelessness in Los Angeles. To address challenges of ML+optimization common to all of these applications\, Dr. Tambe and his team have advanced the state of the art in decision-focused learning\, restless multi-armed bandits and influence maximization in social networks. \nPLEASE CLICK HERE TO REGISTER \n  \nAbout Milind Tambe\, PhD\, MSc \nDr. Milind Tambe is Gordon McKay Professor of Computer Science and Director of Center for Research on Computation and Society at Harvard University; concurrently\, he is also Principal Scientist and Director for “AI for Social Good” at Google Research. Dr. Tambe is a recipient of the AAAI Award for Artificial Intelligence for the Benefit of Humanity\, AAAI Feigenbaum Prize\, IJCAI John McCarthy Award\, AAAI Robert S. Engelmore Memorial Lecture Award\, AAMAS ACM Autonomous Agents Research Award\, INFORMS Wagner prize for excellence in Operations Research practice\, Military Operations Research Society Rist Prize\, and the Columbus Fellowship Foundation Homeland security award. Dr. Tambe is a fellow of AAAI and ACM. Dr. Tambe’s work focuses on advancing AI and multiagent systems for public health\, conservation\, and public safety\, with a track record of building pioneering AI systems for social impact. \nYou can read more about Dr. Milind Tambe on his website\, X\, LinkedIn\, and Facebook. \n  \nAbout the Global Health Research and Innovation Speaker Series \nThe Harvard Global Health Institute’s Global Health Research and Innovation Speaker Series showcases the latest scholarly and scientific advancements in global health across Harvard and beyond\, to make cutting-edge research accessible to a diverse global audience\, and to spark innovative solutions in the pursuit of health equity and improved health outcomes worldwide. The public series takes place virtually on the second Tuesday of each month from 12:00 to 12:45 pm ET. Each session will include a presentation by a featured speaker showcasing their innovative research in global health\, followed by a moderated Q&A. \nSpeakers will share their own perspectives; they do not speak for Harvard. \nPLEASE CLICK HERE TO REGISTER
URL:https://globalhealth.harvard.edu/event/global-health-research-and-innovation-speaker-series-with-milind-tambe/
LOCATION:Zoom\, Virtual: Zoom
ATTACH;FMTTYPE=image/png:https://globalhealth.harvard.edu/wp-content/uploads/2024/03/Research-and-Innovations-Promo-Image-Landscape-1.png
END:VEVENT
END:VCALENDAR